A Phase 2 interventional study of Tonabersat and Placebo in Diabetic Macular Edema, sponsored by Jaeb Center for Health Research. Completed at 28 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Jaeb Center for Health Research · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 32 under way, 11 of them phase 3. Macular Edema · United States.
Among the 276 studies in Macular Edema with a site in United States, this one is the 78th largest by enrollment of the 244 interventional ones that give a count, is one of 11 that started in 2023, is one of 63 in phase 2, and was the 242nd registered.
759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Israel and 1 more country
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 1 more country
Ages 18+
Kodiak Sciences Inc · Sites in United States, Argentina
Ages 18+
Massachusetts Eye and Ear Infirmary · Sites in United States
Ages 18+
Boehringer Ingelheim · Sites in United States, Puerto Rico
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
276 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 74 · Phase 2 101 · Phase 3 57 · Phase 4 33
First in 1992; this study’s year is marked. 11 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 129 is above the median of 56 across 587 interventional studies indexed under Macular Edema.
Median enrollment 45 across the 244 interventional studies, 60 across the 30 observational. Of the 223 that completed or were terminated, 131 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
133 of 276 have an industry lead sponsor. The 10 most frequent:
Jaeb Center for Health Research is the lead sponsor of 129 studies on the registry; 16 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Jaeb Center for Health Research has 9 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
11 of the studies in Macular Edema with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06957080Phase 3EyeBiotech Ltd.A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME | 2027-01-11 |
| NCT06996080Phase 3Kodiak Sciences IncA Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE | 2027-02 |
| NCT06990399Phase 3Kodiak Sciences IncA Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK | 2027-04 |
| NCT04108156Phase 3Hoffmann-La RocheA Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME | 2027-07-20 |
| NCT07449923Phase 3EyePoint Pharmaceuticals, Inc.CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | 2027-10 |
Add all 11 to your calendar (.ics) → With an account.
Among the 276 studies in Macular Edema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.
The primary objective is to assess the effects of tonabersat, an orally administered Connexin43 hemichannel inhibitor, on central subfield thickness (mean change) compared with placebo in eyes with CI-DME and good visual acuity at 6 months.
Exploratory objectives will evaluate biomarkers of kidney function for potential benefit. Furthermore, this phase 2 study is being conducted to determine whether the conduct of a phase 3 trial has merit and provide information on outcome measures needed to design a phase 3 trial.
The criteria were revised on the registry on Nov 20, 2026. See what changed
Key Inclusion Criteria
At least one eye with:
Heidelberg Spectralis: ≥ 305 µm in females, ≥ 320 µm in males
Key Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Placebo
Drug: Tonabersat
Two pills of Study Drug (80 mg tonabersat) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
Two pills of Study Drug (placebo) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
Optical Coherence Tomography Central Subfield Thickness Change From Baseline
Measurements made on the Cirrus device were converted to equivalent measurements as would be assessed on the Spectralis device with the use of the following formula: Spectralis measurement = 40.78 + 0.95 × Cirrus measurement.
Time frame: 6 months
Retinal Volume Change From Baseline
Time frame: 6 months
Optical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema and ≥10% Decrease in CST From Baseline to 6 Months
CI-DME is indicated if Zeiss Cirrus CST: ≥290µm in females and ≥305µm in males or Heidelberg Spectralis CST: ≥305µm in females and ≥320µm in males; Multiple imputation was not performed given the thresholds are gender and machine specific.
Time frame: 6 months
Mean Change in Visual Acuity
Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision. The data presented are the best-corrected visual acuity in the study eye after protocol-defined refraction.
Time frame: 6 months
Received Other Treatment for Diabetic Macular Edema Prior to 6-month Visit
Time frame: 6 months
Received Anti-VEGF Treatment for Diabetic Macular Edema Prior to 6-month Visit
anti-VEGF= antivascular endothelial growth factor
Time frame: 6 months
| Milestone | Placebo | Tonabersat (80 mg) |
|---|---|---|
| Started | 65 | 64 |
| Completed | 60 | 61 |
| Not completed | 5 | 3 |
| Withdrew: Missed visit | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Death | 1 | 0 |
Measurements made on the Cirrus device were converted to equivalent measurements as would be assessed on the Spectralis device with the use of the following formula: Spectralis measurement = 40.78 + 0.95 × Cirrus measurement.
| Microns | Placebo | Tonabersat (80 mg) |
|---|---|---|
| Optical Coherence Tomography Central Subfield Thickness Change From Baseline | 5 ± 51 | -15 ± 55 |
| mm^3 | Placebo | Tonabersat (80 mg) |
|---|---|---|
| Retinal Volume Change From Baseline | 0.03 ± 0.30 | -0.12 ± 0.42 |
CI-DME is indicated if Zeiss Cirrus CST: ≥290µm in females and ≥305µm in males or Heidelberg Spectralis CST: ≥305µm in females and ≥320µm in males; Multiple imputation was not performed given the thresholds are gender and machine specific.
| Eyes | Placebo | Tonabersat (80 mg) |
|---|---|---|
| Optical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema and ≥10% Decrease in CST From Baseline to 6 Months | 3 | 8 |
Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision. The data presented are the best-corrected visual acuity in the study eye after protocol-defined refraction.
| Letter Score | Placebo | Tonabersat (80 mg) |
|---|---|---|
| Mean Change in Visual Acuity | -0.4 ± 5.7 | 0 ± 5.7 |
| Eyes | Placebo | Tonabersat (80 mg) |
|---|---|---|
| Received Other Treatment for Diabetic Macular Edema Prior to 6-month Visit | 5 | 4 |
anti-VEGF= antivascular endothelial growth factor
| Eyes | Placebo | Tonabersat (80 mg) |
|---|---|---|
| Received Anti-VEGF Treatment for Diabetic Macular Edema Prior to 6-month Visit | 7 | 4 |
Collected over 6 months. Non-serious events are listed at a 0.01% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/65 (1.5%) | 10/65 (15.4%) | 50/65 (76.9%) |
| Tonabersat (80 mg) | 0/64 (0%) | 14/64 (21.9%) | 46/64 (71.9%) |
| Event | Placebo | Tonabersat (80 mg) |
|---|---|---|
| Congestive heart failureCardiac disorders | 0/65 | 2/64 |
| DizzinessNervous system disorders | 0/65 | 2/64 |
| Atrial fibrillationCardiac disorders | 0/65 | 1/64 |
| Cardiac arrhythmiaCardiac disorders | 0/65 | 1/64 |
| Heart failureCardiac disorders | 1/65 | 1/64 |
| TachycardiaCardiac disorders | 0/65 | 1/64 |
| HypoglycemiaEndocrine disorders | 0/65 | 1/64 |
| SepsisInfections and infestations | 0/65 | 1/64 |
| Sacroiliac joint dysfunctionMusculoskeletal and connective tissue disorders | 0/65 | 1/64 |
| Shoulder painMusculoskeletal and connective tissue disorders | 0/65 | 1/64 |
| Event | Placebo | Tonabersat (80 mg) |
|---|---|---|
| DizzinessNervous system disorders | 7/65 | 16/64 |
| HeadacheNervous system disorders | 12/65 | 5/64 |
| Urine albumin/creatinine ratio increasedInvestigations | 9/65 | 10/64 |
| DrowsinessNervous system disorders | 7/65 | 7/64 |
| Diabetic macular edemaEye disorders | 7/65 | 3/64 |
| ColdRespiratory, thoracic and mediastinal disorders | 2/65 | 6/64 |
| C-reactive protein result highInvestigations | 6/65 | 4/64 |
| Glucose highInvestigations | 2/65 | 5/64 |
| Albumin increasedInvestigations | 5/65 | 1/64 |
| NauseaGastrointestinal disorders | 1/65 | 4/64 |
Units in Eyes: 7 participants in the Tonabersat group and 8 participants in the Placebo group enrolled in two study eyes
| Age, Continuous(years) | Placebo | Tonabersat (80 mg) | Total |
|---|---|---|---|
| Mean | 63 ± 10 | 63 ± 10 | 63 ± 10 |
| Sex/Gender, Customized(Participants) | Placebo | Tonabersat (80 mg) | Total |
|---|---|---|---|
| Female | 26 | 22 | 48 |
| Male | 39 | 42 | 81 |
| Race/Ethnicity, Customized(Participants) | Placebo | Tonabersat (80 mg) | Total |
|---|---|---|---|
| White | 42 | 41 | 83 |
| Black/African American | 10 | 13 | 23 |
| Hispanic or Latino | 12 | 8 | 20 |
| More than one race | 1 | 1 | 2 |
| Unknown/not reported | 0 | 1 | 1 |
| Type of diabetes(Participants) | Placebo | Tonabersat (80 mg) | Total |
|---|---|---|---|
| Type 1 | 3 | 2 | 5 |
| Type 2 | 62 | 62 | 124 |
| Duration of diabetes(years) | Placebo | Tonabersat (80 mg) | Total |
|---|---|---|---|
| Mean | 16 ± 11 | 19 ± 10 | 17 ± 11 |
| Glycated hemoglobin(Hemoglobin A1c percentage) | Placebo | Tonabersat (80 mg) | Total |
|---|---|---|---|
| Mean | 7.5 ± 1.2 | 7.1 ± 1.2 | 7.3 ± 1.2 |
| Visual acuity letter score(Letter Score) | Placebo | Tonabersat (80 mg) | Total |
|---|---|---|---|
| Mean | 83 ± 4 | 84 ± 4 | 83 ± 4 |
| Central subfield thickness(Microns) | Placebo | Tonabersat (80 mg) | Total |
|---|---|---|---|
| Mean | 362 ± 59 | 359 ± 63 | 360 ± 61 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2023 to primary completion in Jan 2026, 32 months.
Results were first posted in Nov 2026, 10 months after primary completion.
Of 50 phase 2 interventional studies under Macular Edema, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's 32 months is above that.
Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2025 → Jan 2026, on Nov 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tonabersat
Jaeb Center for Health Research →